1. Home
  2. CTNM vs JMSB Comparison

CTNM vs JMSB Comparison

Compare CTNM & JMSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • JMSB
  • Stock Information
  • Founded
  • CTNM 2009
  • JMSB 2005
  • Country
  • CTNM United States
  • JMSB United States
  • Employees
  • CTNM N/A
  • JMSB N/A
  • Industry
  • CTNM
  • JMSB Major Banks
  • Sector
  • CTNM
  • JMSB Finance
  • Exchange
  • CTNM Nasdaq
  • JMSB Nasdaq
  • Market Cap
  • CTNM 378.7M
  • JMSB 308.2M
  • IPO Year
  • CTNM 2024
  • JMSB N/A
  • Fundamental
  • Price
  • CTNM $14.14
  • JMSB $21.75
  • Analyst Decision
  • CTNM Strong Buy
  • JMSB
  • Analyst Count
  • CTNM 4
  • JMSB 0
  • Target Price
  • CTNM $29.25
  • JMSB N/A
  • AVG Volume (30 Days)
  • CTNM 82.5K
  • JMSB 13.7K
  • Earning Date
  • CTNM 11-06-2024
  • JMSB 01-22-2025
  • Dividend Yield
  • CTNM N/A
  • JMSB 1.15%
  • EPS Growth
  • CTNM N/A
  • JMSB 89.06
  • EPS
  • CTNM N/A
  • JMSB 1.18
  • Revenue
  • CTNM N/A
  • JMSB $53,070,000.00
  • Revenue This Year
  • CTNM N/A
  • JMSB N/A
  • Revenue Next Year
  • CTNM N/A
  • JMSB N/A
  • P/E Ratio
  • CTNM N/A
  • JMSB $18.44
  • Revenue Growth
  • CTNM N/A
  • JMSB 22.25
  • 52 Week Low
  • CTNM $12.33
  • JMSB $15.00
  • 52 Week High
  • CTNM $22.00
  • JMSB $26.52
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • JMSB 42.50
  • Support Level
  • CTNM N/A
  • JMSB $21.27
  • Resistance Level
  • CTNM N/A
  • JMSB $22.20
  • Average True Range (ATR)
  • CTNM 0.00
  • JMSB 0.63
  • MACD
  • CTNM 0.00
  • JMSB -0.21
  • Stochastic Oscillator
  • CTNM 0.00
  • JMSB 20.96

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About JMSB John Marshall Bancorp Inc.

John Marshall Bancorp Inc provides banking services. The company offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.

Share on Social Networks: